HLA-DRB5: A Promising Drug Target / Biomarker (G3127)

Target Name: HLA-DRB5

NCBI ID: G3127

HLA-DRB5

HLA-DRB5: A Promising Drug Target / Biomarker

HLA-DRB5 is a human leukocyte antigen (HLA) gene that is located on chromosome 6 and has been identified as a potential drug target or biomarker for various diseases. The HLA-DRB5 gene is a member of the major histocompatibility complex (MHC) and is responsible for the production of the DRB5 antigen, which is a key component of the immune system. HLA-DRB5 has been shown to play a crucial role in the immune response and has been implicated in a number of diseases, including autoimmune disorders, cancer, and neurodegenerative diseases.

Drug Target Potential

HLA-DRB5 has been identified as a potential drug target due to its involvement in the immune response and its association with a number of diseases. One of the main reasons for its potential as a drug target is its expression in a variety of tissues and cells, including immune cells, tissues, and organs. Additionally, HLA-DRB5 has been shown to play a role in the regulation of immune responses and has been shown to be involved in the development and progression of autoimmune diseases.

Another potential mechanism by which HLA-DRB5 could be targeted as a drug is its association with cancer. Studies have shown that HLA-DRB5 is often expressed in various types of cancer, including breast, lung, and colorectal cancer. Additionally, HLA-DRB5 has been shown to promote the growth and survival of cancer cells, which could make it an attractive target for cancer treatments.

Biomarker Potential

HLA-DRB5 has also been identified as a potential biomarker for a number of diseases. One of the main reasons for its potential as a biomarker is its expression in a variety of tissues and cells, including immune cells, which could make it an attractive target for diagnostic tests. Additionally, HLA-DRB5 has been shown to be involved in the regulation of immune responses, which could make it an attractive target for therapies aimed at modulating the immune system.

Conclusion

HLA-DRB5 is a human leukocyte antigen that has been identified as a potential drug target and biomarker for a variety of diseases. Its expression in a variety of tissues and cells, including immune cells, makes it an attractive target for therapies aimed at modulating the immune system. Additionally, its association with the immune response and its involvement in the regulation of immune responses make it a potential drug target for diseases that are characterized by an imbalance of the immune system. Further research is needed to fully understand the potential of HLA-DRB5 as a drug target and biomarker.

Protein Name: Major Histocompatibility Complex, Class II, DR Beta 5

Functions: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading

The "HLA-DRB5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-DRB5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets